Vitamin K2 for Heart Health and Arterial Calcification

The cardiovascular case for vitamin K2 rests on a single protein: matrix Gla protein (MGP), the most powerful natural brake the body has on calcification of artery walls. K2 is what activates it. The supporting evidence is a genuinely interesting mix — a mouse that calcifies to death without MGP, a landmark population study (the Rotterdam Study) linking higher K2 intake to less heart disease, a small randomized trial showing MK-7 improved arterial stiffness, and the striking observation that the anticoagulant warfarin, which blocks vitamin K, accelerates arterial calcification. It is a compelling, mechanistically coherent story. It is also, honestly, not proven: the human data are largely observational or use surrogate endpoints, and the Cochrane review concluded there is not yet enough randomized evidence to say vitamin K prevents heart attacks or strokes. This page presents both the promise and the limits without inflating either.

Table of Contents

  1. Matrix Gla Protein: The Arterial Calcification Brake
  2. How Arteries Calcify (and Why It Matters)
  3. The MGP-Knockout Mouse: Proof of Principle
  4. The Rotterdam Study: The Landmark Association
  5. Other Cohort Evidence (Beulens, Gast)
  6. The MK-7 Arterial Stiffness Trial
  7. The Warfarin Clue: Blocking K Causes Calcification
  8. What Is Not Yet Proven (Honest Limits)
  9. Who Might Reasonably Consider K2
  10. Cautions (Warfarin First)
  11. Key Research Papers
  12. External Resources
  13. Connections
  14. Featured Videos

Matrix Gla Protein: The Arterial Calcification Brake

Matrix Gla protein (MGP) is a small protein made by the smooth-muscle cells of artery walls and by cartilage cells. Its job is to prevent calcium from crystallizing where it should not — in the elastic and muscular layers of blood vessels and in soft tissue. It does this by binding calcium ions and calcium-phosphate crystals directly and holding them in check.

Like osteocalcin in bone, MGP only works when it has been activated by vitamin-K-dependent carboxylation. Freshly made MGP is uncarboxylated and inactive; the enzyme gamma-glutamyl carboxylase, using vitamin K as its cofactor, converts glutamate residues into calcium-binding Gla residues, switching MGP into its protective form. When vitamin K is scarce, MGP is produced but stays in its dephospho-uncarboxylated form (dp-ucMGP) — unable to guard the vessel wall. Circulating dp-ucMGP can be measured in blood and is used in research as a marker of vitamin K status; higher levels have been associated with more vascular calcification and higher cardiovascular risk in observational studies (Schurgers 2008).

Because MGP acts locally in the artery wall and because the long-acting menaquinone MK-7 reaches those extra-hepatic tissues well, vitamin K2 is the form most discussed for cardiovascular protection — the same logic that applies to osteocalcin and bone.

Back to Table of Contents

How Arteries Calcify (and Why It Matters)

Arterial calcification is not simply calcium passively "clogging up" with age. It is an active, regulated process in which vascular smooth-muscle cells can take on bone-cell-like behavior and deposit mineral in the vessel wall. Two patterns matter: calcification within atherosclerotic plaques (associated with plaque burden), and medial calcification of the artery wall itself (Monckeberg-type), which stiffens the artery.

Stiff, calcified arteries do not expand and recoil normally with each heartbeat. This raises systolic blood pressure and pulse pressure, increases the workload on the heart, and is an independent predictor of cardiovascular events. Coronary artery calcium (CAC) scoring by CT is one of the strongest available predictors of future heart attack. So anything that plausibly slows arterial calcification is of real interest — and MGP, the master local inhibitor of that process, is vitamin-K-dependent. That is the entire mechanistic basis for the K2-and-heart hypothesis. The question is whether feeding the system more K2 measurably changes outcomes, which the later sections address honestly. For the disease context, see Atherosclerosis and Cardiovascular Disease.

Back to Table of Contents

The MGP-Knockout Mouse: Proof of Principle

The most dramatic demonstration that MGP protects arteries came from Luo and colleagues (1997), published in Nature. They engineered mice that could not make matrix Gla protein at all. The result was severe and fast: the mice developed massive calcification of the aorta and other arteries, plus abnormal cartilage calcification, and died within about two months from blood-vessel rupture caused by the loss of arterial elasticity.

This experiment established, unambiguously in an animal model, that MGP is essential for keeping arteries free of calcification — its complete absence is lethal through arterial calcification alone. Because MGP requires vitamin K to be activated, the knockout mouse is the strongest single piece of biological evidence tying the vitamin-K/MGP axis to vascular health. It is proof of principle for the mechanism. What it does not prove is that giving extra K2 to a person with an intact, functioning MGP system prevents heart attacks — a person is not a knockout mouse, and having more of a cofactor than you need does not always help.

Back to Table of Contents

The Rotterdam Study: The Landmark Association

The single most-cited human study is the Rotterdam Study analysis by Geleijnse and colleagues (2004). This large Dutch prospective cohort followed several thousand older adults and analyzed dietary vitamin K intake against cardiovascular outcomes over roughly 7–10 years. The key finding: people in the highest third of dietary menaquinone (K2) intake had significantly lower coronary heart disease mortality, lower all-cause mortality, and less severe aortic calcification than those in the lowest third. Crucially, dietary phylloquinone (K1) intake showed no such association — the benefit tracked specifically with K2, which fits the MGP mechanism and the better tissue reach of menaquinones.

This is a strong, biologically coherent association. But it is an association from an observational cohort, and that carries the usual limits: dietary K2 in this population came heavily from cheese and other animal/fermented foods, and people who eat differently also differ in other ways. Observational cohorts cannot, by design, prove that the K2 itself caused the lower heart-disease rates rather than some correlated factor. The Rotterdam Study is the reason people take K2 and heart health seriously; it is not, and was never claimed to be, proof of a causal preventive effect.

Back to Table of Contents

Other Cohort Evidence (Beulens, Gast)

Two Dutch cohort analyses reinforce the Rotterdam pattern:

The consistency across independent cohorts — K2 (not K1) associated with less calcification and less coronary disease — strengthens the hypothesis. It does not overcome the fundamental limitation that all three are observational. Multiple consistent cohorts raise confidence but cannot substitute for a randomized outcome trial.

Back to Table of Contents

The MK-7 Arterial Stiffness Trial

The best randomized evidence to date is the trial by Knapen and colleagues (2015), published in Thrombosis and Haemostasis. It randomized 244 healthy postmenopausal women to 180 mcg/day of MK-7 or placebo for three years. Results:

This is a real, placebo-controlled, three-year randomized trial showing MK-7 improved an established cardiovascular surrogate marker (arterial stiffness) and moved the MGP biomarker in the protective direction. Companion work in coronary artery calcium (for example, Shea 2009 using vitamin K1 at 500 mcg/day) showed slowed progression of coronary calcium in a subgroup, adding to the surrogate-endpoint picture. The honest framing: arterial stiffness and calcium scores are predictors of events, not events themselves. Improving a surrogate is promising and consistent with the mechanism, but it is not the same as demonstrating fewer heart attacks, strokes, or cardiovascular deaths.

Back to Table of Contents

The Warfarin Clue: Blocking K Causes Calcification

One of the most persuasive lines of evidence comes from the opposite direction — what happens when vitamin K is deliberately blocked. Warfarin and related coumarin anticoagulants work by inhibiting the recycling of vitamin K, which reduces carboxylation of all vitamin-K-dependent proteins, MGP included. If MGP truly protects arteries, then chronic warfarin should promote arterial calcification. It does.

This "block the vitamin, get more calcification; restore the vitamin, slow or regress it" symmetry is strong mechanistic support for MGP's protective role in people, not just mice. It is also the sharpest possible reminder of the central safety point on this page: because warfarin's therapeutic effect depends on limiting vitamin K, anyone taking warfarin must not add vitamin K/K2 supplements without their prescriber's direction — doing so opposes the drug and can dangerously destabilize anticoagulation.

Back to Table of Contents

What Is Not Yet Proven (Honest Limits)

To be clear about where the science actually stands:

  1. No completed randomized trial has shown that vitamin K2 prevents cardiovascular events (heart attack, stroke, cardiovascular death) in a general population. The human trials measure surrogates: arterial stiffness, coronary calcium progression, and the dp-ucMGP biomarker.
  2. The Cochrane systematic review (Hartley 2015) on vitamin K for the primary prevention of cardiovascular disease concluded there was insufficient randomized evidence to determine an effect — too few outcome trials to draw conclusions.
  3. The cohort evidence is observational and cannot establish causation, however consistent it is.
  4. Ongoing and specialized trials (for example, in dialysis and coronary-artery-disease populations, where dp-ucMGP is high) are testing whether K2 slows calcification in higher-risk groups; results in such populations have been mixed and do not yet settle the question.

So the accurate statement is: vitamin K2 for heart health is a promising, mechanistically well-grounded hypothesis supported by animal models, consistent observational cohorts, and small surrogate-endpoint trials — but it is not an established, outcome-proven therapy. Anyone claiming K2 is proven to prevent heart attacks is overstating the evidence.

Back to Table of Contents

Who Might Reasonably Consider K2

Back to Table of Contents

Cautions (Warfarin First)

Back to Table of Contents

Key Research Papers

  1. Luo G et al. (1997). Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. — PubMed 9052783
  2. Schurgers LJ, Cranenburg ECM, Vermeer C (2008). Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost. — PubMed 18841280
  3. Geleijnse JM et al. (2004). Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr. — PubMed 15514282
  4. Beulens JW et al. (2009). High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis. — PubMed 18722618
  5. Gast GC et al. (2009). A high menaquinone intake reduces the incidence of coronary heart disease. Nutr Metab Cardiovasc Dis. — PubMed 19179058
  6. Knapen MHJ et al. (2015). Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: a double-blind randomised clinical trial. Thromb Haemost. — PubMed 25694037
  7. Shea MK et al. (2009). Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am J Clin Nutr. — PubMed 19386744
  8. Schurgers LJ et al. (2007). Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood. — PubMed 17138823
  9. Rennenberg RJMW et al. (2010). Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans. Blood. — PubMed 20354170
  10. Theuwissen E, Smit E, Vermeer C (2012). The role of vitamin K in soft-tissue calcification. Adv Nutr. — PubMed 22516724
  11. Hartley L et al. (2015). Vitamin K for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. — PubMed 26389791

PubMed Topic Searches

  1. PubMed: MGP & arterial calcification
  2. PubMed: menaquinone & coronary heart disease
  3. PubMed: MK-7 & arterial stiffness
  4. PubMed: dp-ucMGP biomarker
  5. PubMed: warfarin & vascular calcification

Back to Table of Contents

External Resources

Back to Table of Contents

Connections

Back to Table of Contents